BNET Industries
Market Cap:$262.1M
Last Fiscal Year Sales:$47.1M
- Public
- US
Dow Jones Description
We are a genetics company committed to providing genetic analysis products, services and diagnostic applications. Our products and services are designed to translate the results of genomic research into solutions for biomedical research, translational research, molecular medicine applications and research conducted in the agro (agricultural and livestock) industry. Our development efforts in various diagnostic applications include areas of noninvasive diagnostics in prenatal, oncology and infectious diseases and other disorders. Our proprietary MassARRAY system, comprised of hardware, software applications, consumable chips and reagents, is a high performance (in speed, accuracy and cost efficiency) nucleic acid analysis platform that quantitatively and precisely measures genetic target material and variations. Our MassARRAY research and development efforts are committed to producing new and improved components and applications that deliver greater system versatility and reduce the cost per data point generated. MassARRAY technology is widely accepted as a leading high-performance DNA analysis platform for the fine mapping genotyping and quantitative gene expression markets and is gaining traction in new developing markets, such as epigenomics and pathogen typing. Our customers include some of the worldwide premier clinical research laboratories, biotechnology companies and academic institutions, as well as various government agencies. ...
Number of Employees 248
Contact Information
3595 John Hopkins Ct
San Diego, California 92121-1331
(858) 202-9000
Peer Companies
NAICS Code : 541710
Recent Events
-
PicksThatMove.com Announces Investment Opinion on Sequenom Inc., Gabriel Resources Ltd., Rentech Inc., Imaging 3 Inc.,...
-
Sequenom Q3 Loss Widens - Update
-
Sequenom faces fraud suit from Xenomics
-
Sequenom, Ibis settle lawsuit
-
Sequenom names Maier as interim CFO
-
ATVI, RMBS, MRVL, SQNM, ERIC, AKAM With Highest Daily Short Volume On
-
Sequenom discloses probes following firings
-
Sequenom ousts CEO, other execs
-
Sequenom tumbles after execs fired amid test woes
-
Investors Remain Hopeful About Sequenom's Prospects
-
Sequenom Ousts CEO After Finding Errors, Inconsistencies In Down Syndrome Test; CFO Resigns
News & Analysis
Filter by
biotech and sequenom inc. - All News and Analysis
Sequenom: Heads Roll, Investors Struggle to Find the Bottom
Brendan Wagner submits: After an independent board investigation, Sequenom SQNM has fired arguably the three most important people in a biotech outfit - its CEO, CFO, and head of Research & Development. At the bottom of this piece is a look at attempts to peg a fair value for these...
Something's Rotten in the State of Sequenom (But Who Really Cares?)
Trader Mark submits: The drama never ceases at Sequenom SQNM; there appears to be a purging of upper management after investigations into what went wrong with the company's Down Syndrome's test. [Apr 29, 2009: Sequenom Bombshell] After *that* revelation (and stock plunge from $15 to $3s) speculators have returned to...
Sequenom Reaches Important Milestone
Hello future. It did not take us long to welcome the arrival of what many have expected from Sequenom SQNM and many have doubted. The expected has, indeed, begun to show, and the doubt that should disappear will stay as long as the skeptics of Wall street are ideologists...
Spectrum Pharmaceuticals, Sequenom Shares Rise on Heavy Volume
Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) jumped on twice the average volume Monday. Shares for the biopharmaceutical company, which focuses on pioneering novel cancer therapies with a focus primarily in the areas of hematology-oncology and urology, are under a heavy accumulation which is related to Spectrum’s dealings with the FDA,...
Who Sold Sequenom Last Week and Why?
Sequenom’s SQNM recent stock decline looked as if a program was set for selling SQNM as soon as the financial results were announced. The point is that the firm’s financial results had nothing to do with SQNM's price move, neither during the rally that took the stock up from a...
SEQUENOM, Inc. Q2 2009 Earnings Call Transcript
SEQUENOM, Inc. SQNM Q2 2009 Earnings Call August 6, 2009 4:30 am ET
Sequenom and the Small Cap Biotech Bipolar Experience
Trader Mark submits: Still keeping my eye on the Sequenom SQNM, but the whole idea with this name was to avoid the small cap "biotech" bipolar experience either a huge win or a huge loss. Unfortunately, this is what this has now turned to, a coin flip. Probably the most...
The Sequenom Syndrome
Mike Huckman submits: Shares of San Diego-based Sequenom SQNM are sinking on huge trading volume. The company shocked investors after the closing bell yesterday when it issued this press release announcing that its data couldn't be trusted. by Mike Huckman
Sequenom Misses Earnings Again
Trader Mark submits:Sequenom SQNM reported Tuesday night, but as I said last quarter [Oct 30: Sequenom Misses But We Don't Really Care], and will say next quarter and the quarter after that ... earnings "today" don't mean diddly in this story. The main focus for Sequenom for now is cash...
Sequenom Is Put to the Test
Mike Huckman submits: I need a break from blogging all-things Pfizer PFE. Sequenom SQNM to the rescue. Wednesday night at an investor/analyst meeting tied to a scientific conference and in a press release, Sequenom unveiled more data on its diagnostic test for Down Syndrome. Out of nearly 900 women...
- 1
- 2
IndustryTop Rated
- Google Offers Free Downloads of a Million Books 11 votes
- InsideView Disrupts Legacy Business Info Publishers Like Hoover's 9 votes
- Mobile is the New Mass Medium, For Better or Worse 8 votes
- As Income Mobility Falls, American Dream Fades 7 votes
- PeopleMaps: Leveraging Those Followers and Friends 6 votes


